Dead BC - From FFWD March F/S1 Aug 2018 11:15
The Diabetic Boot Company Limited
DBC, which trades under the name "Pulseflow", has developed a new form of diabetic friendly footwear with integrated offloading capabilities and the patented Pulseflow technology which aids in the promotion of blood flow and improved circulation in one product.
Â
During the year ended 31 March 2018, the application of a new product specific code from the U.S. Centres for Medicare & Medicaid Services ("Medicare") for PulseFlowDF by Diabetic Boot was rejected. As management expects Medicare to require additional clinical data and justification of product need in the US market before granting a code, there is no definite timeline to do so. In addition, in view of the recurring operating losses of Diabetic Boot, the Directors of the Company consider that indicators of impairment existed in respect of the investment in Diabetic Boot and accordingly, an impairment loss of £347k has been recognised in profit or loss for the Company's interests in Diabetic Boot for the year ended 31 March 2018.